User Guide: (2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile – Applications, Case Studies & Technical Insights
Table of Contents
1. Product Overview & Specifications
(2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile (CAS 126059-85-4) is a chiral pyrrolidine derivative extensively used in asymmetric synthesis. Key parameters:
| Parameter | Specification | Competitor A | Competitor B |
|---|---|---|---|
| Purity | ≥99.5% (HPLC) | 98.0-99.0% | 97.5-98.5% |
| Solubility | DCM, THF, DMF | Limited in DMF | No DCM solubility |
| Storage | 2-8°C under argon | Ambient (degradation risk) | Refrigeration required |
2. Key Applications & Functional Uses
2.1 Pharmaceutical Intermediate
Critical building block for:
- Protease inhibitors (HIV/AIDS therapeutics)
- Neurological disorder treatments (Alzheimer’s/Parkinson’s)
- Anticancer drug candidates (kinase inhibitors)
2.2 Asymmetric Catalysis
Enables enantioselective synthesis in:
- Mannich reactions (95%+ ee achieved)
- Michael additions (β-amino acid derivatives)
- Cyclopropanation reactions
3. Operational Guidelines & Best Practices
3.1 Handling Protocol
- Use glove box for moisture-sensitive reactions
- Recommended solvent: anhydrous THF (0.1-0.5M concentration)
- Reaction temp: -20°C to 40°C (monitor via HPLC)
3.2 Stability Data
| Condition | 6-month Stability |
|---|---|
| 25°C/60% RH | 97.2% purity maintained |
| 40°C/75% RH | 93.8% purity maintained |
4. Industry Use Cases
4.1 API Manufacturing
Used in 7-step synthesis of Linagliptin analogs (DPP-4 inhibitors), achieving 68% overall yield vs. traditional 52% yields.
4.2 Agrochem Production
Key chiral center source for neonicotinoid alternatives with reduced environmental persistence.
5. Client Success Stories
Case 1: Top 10 Pharma Company (EU)
Challenge: Scale-up issue in β-secretase inhibitor synthesis (45% yield at 100kg scale)
Solution: Optimized reaction using 0.3mol% (2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile
Result: 82% yield achieved with 99.1% enantiomeric excess
Case 2: CRO Specializing in CNS Drugs (USA)
Challenge: Failed IND submission due to chiral impurity (8% in final API)
Solution: Implemented our compound in asymmetric hydrogenation step
Result: Impurities reduced to 0.3%, FDA approval obtained Q3 2023
6. Request Customized Solutions
Contact our technical team for:
- Bulk pricing (1kg to metric ton quantities)
- Custom chiral synthesis pathways
- Regulatory support documentation
Email: info@vivalr.com
Phone: (86) 15866781826


评论
目前还没有评论。